title: [Personalized medicine in cytokine-targeted therapy].
abstract: Personalized healthcare tries to predict the effectiveness and safety in individual therapeutic approaches by defining individual patient characteristics (biomarkers), while stratification uses diagnostic patterns for groups of patients for prediction of therapeutic response with less adverse reactions caused by the drugs applied. Both methods are implemented in oncology and infectiology and in the therapy of rheumatological diseases there is a need for both. Cytokine-directed therapies are important for the treatment of rheumatological diseases, especially when therapy with conventional disease-modifying antirheumatic drugs (DMARD) has failed. Despite the high potency of these drugs for inhibiting pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin 1 (IL-1) and IL-6, sufficient responses are only seen in some of the patients. Therefore, stratification and personalized medicine are ways to optimize efficacy and tolerability of biologic therapies. Some initial evidence is available for potential future strategies using molecular and genetic markers for stratified cytokine inhibition.
authors: CIRI/Rheumatologie, Klinikum Johann Wolfgang Goethe - Universität, 60590, Frankfurt am Main. Frank.Behrens@kgu.de
authors: F
authors: F
authors: Behrens
authors: M
authors: M
authors: Köhm
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000276:immunology*; D006801:Humans; D057285:Precision Medicine / Q000639:trends*; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000276:immunology*; D012219:Rheumatology / Q000639:trends*
chemical_list: D018501:Antirheumatic Agents; D016207:Cytokines
references: Arthritis Rheum. 2000 Nov;43(11):2391-6
references: 11083259
references: Arthritis Rheum. 2009 May;60(5):1565-6
references: 19404928
references: Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v3-11
references: 22718924
references: Arthritis Rheum. 2012 Nov;64(11):3502-10
references: 22886739
references: Autoimmun Rev. 2012 Aug;11(10):699-704
references: 22197901
references: N Engl J Med. 2012 Aug 9;367(6):565-7
references: 22873537
references: J Eval Clin Pract. 2012 Oct;18(5):1000-5
references: 22994998
references: J Clin Invest. 1998 Oct 1;102(7):1369-76
references: 9769329
references: Arthritis Rheum. 1992 Oct;35(10):1160-9
references: 1329774
references: Ann Rheum Dis. 2004 May;63(5):508-16
references: 15082480
references: PLoS One. 2011;6(12):e29492
references: 22242124
references: Lancet. 2008 Mar 22;371(9617):987-97
references: 18358926
references: Rheumatology (Oxford). 2012 Sep;51(9):1639-43
references: 22596214
references: Curr Opin Rheumatol. 2012 Jul;24(4):351-8
references: 22488076
references: JAMA. 2011 Dec 7;306(21):2331-9
references: 22056398
references: Rheumatology (Oxford). 2011 Aug;50(8):1487-93
references: 21454308
references: Ann Med. 2011 Nov;43(7):503-11
references: 21585245
references: Rheumatology (Oxford). 2012 Apr;51(4):600-9
references: 21890615
references: Arthritis Rheum. 2006 Apr;54(4):1122-31
references: 16572447
references: Arthritis Rheum. 2010 Jul;62(7):1849-61
references: 20309874
references: Ann Rheum Dis. 2012 Jun;71(6):1055-63
references: 22267334
references: Mol Psychiatry. 2011 Mar;16(3):321-32
references: 20195266
references: N Engl J Med. 2005 Sep 15;353(11):1114-23
references: 16162882
references: Ann Rheum Dis. 2008 Aug;67(8):1139-44
references: 18055470
references: JAMA. 2009 Feb 18;301(7):737-44
references: 19224750
references: J Exp Med. 2007 Sep 3;204(9):2131-44
references: 17724127
references: Am J Surg. 1991 Jun;161(6):639-45
references: 1862821
references: Arthritis Rheum. 2006 Sep;54(9):2793-806
references: 16947627
references: J Biomed Biotechnol. 2012;2012:347141
references: 22500087
references: Open Rheumatol J. 2012;6:33-7
references: 22655000
references: Arthritis Rheum. 2009 Nov;60(11):3217-24
references: 19877042